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Abstract  
 
This paper estimates the increase of direct medical costs of both severe and moderate obesity 
and overweight with respect to a normal-weight individual using a two-part generalised linear 
model and a longitudinal dataset of medical and administrative records of patients in primary and 
secondary healthcare centres followed up over seven consecutive years (2004–2010) in Spain. 
Our findings indicate that severe and moderate obesity imposes a substantial burden on the 
Spanish healthcare system. Specifically, being severely obese is associated with increases in 
medical costs of 26 % (instrumental variables (IV) estimate, 34 %) compared to a normal-weight 
individual. The effects of moderate obesity and overweight are more modest, raising medical 
costs by 16 % (IV estimate, 29 %) and 8.5 % (IV estimate, 23 %), respectively. These changes in 
costs are slightly higher for those patients below the median age and for the women. 
Notwithstanding, the effects found in this study are comparatively much lower than that reported 
for the USA, based basically on a private healthcare system and characterised by a more obese 
population. 
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1. Introduction 
 
 
Obesity is a complex, multifactorial, chronic disease involving genetic, perinatal, and 
environmental components. Its prevalence in Europe in the last two decades has tripled and 
150 million adults and 15 million children and adolescents in the region are today estimated 
to be obese (Berghöfer et al., 2008). After the United Kingdom, Spain is the EU country to 
have recorded the highest increases in its standardised rate of obesity over this period (OECD, 
2012) and ranks high in terms of overweight and obesity levels on the continent. The latest 
data from the European Health Survey (2009) report that 38% (16%) of Spanish adults are 
overweight (obese) (cf. OECD, 2012). 
The condition is a major public health concern since obesity is a key risk factor for a 
range of chronic illnesses (including, hypertension, diabetes, cholesterol, heart disease, stroke, 
gallbladder disease, biliary calculus, narcolepsy, osteoarthritis, asthma, apnoea, 
dyslipidaemia, gout and certain cancers) that tend to reduce the quality of life and ultimately 
result in death (Alberti et al., 2009; López-Suárez et al., 2008). Additionally, a significant 
number of obese patients tend to suffer mental disorders and social rejection leading to a loss 
of self-esteem, a particularly sensitive issue in the case of children (Gariepy et al., 2010). 
Given its prevalence and association with multiple chronic illnesses, obesity tends to increase 
healthcare resource utilisation and costs substantially. 
The aim of the paper is to estimate the increase of direct medical costs of both severe 
(BMI ≥ 35 kg/m2) and moderate (30 ≤ BMI < 35 kg/m2) obesity and also overweight (25 ≤ 
BMI < 30 kg/m2) with respect to a normal-weight individual, using a two-part generalised 
linear model and a longitudinal dataset based on medical and administrative records of 
patients in primary and secondary healthcare centres followed up over seven consecutive 
years (2004-2010) in Spain. The effect of BMI and two additional methodological 
frameworks are also examined for robustness purposes. Since medical costs and obesity/ 
overweight may have an endogenous relationship an IV estimation is additionally performed 
based on children’s information. This is, as far as we know, the first application exploring the 
impact of body weight on healthcare costs using longitudinal information containing objective 
health, weight and height (and consequently the BMI) measurements. Then, we report 
findings for the association between body weight and healthcare costs in a European country 
whose healthcare centres operate under a typical NHS and strict cost-containment policies 
were implemented during the period of analysis.  
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Our results indicate that severe and moderate obesity imposes a substantial burden on 
the Spanish health care system. Specifically, being severely obese is associated with increases 
in medical costs of 26% (IV estimate: 34%) compared to a normal-weight individual. The 
effects of moderate obesity and overweight are more modest raising medical costs by 16% 
(IV estimate: 29%) and 8.5% (IV estimate: 23%), respectively. These changes in costs are 
slightly higher for those patients below the median age and for the women. Notwithstanding, 
the effects found in this study are comparatively much lower than that reported for the US, 
based basically on a private healthcare system and characterised by a more obese population. 
The paper is organised as follows: Section 2 presents the related literature; Section 3 
describes the empirical strategy; Section 4 describes the data; Section 5 presents the results, 
Section 6 discusses the main policy implications of the findings and Section 7 concludes. 
 
2. Related Literature 
 
A sizeable body of literature quantifies the magnitude of healthcare expenditure associated 
with the obesity condition. Barrett et al. (2008) distinguish two different lines of research on 
the subject. Thus, one set of studies concerns itself with the estimation of annual direct costs 
of obesity at an aggregate level. Most of them follow an “etiologic fraction” approach and 
consider the most frequent obesity-related diseases (Wolf and Colditz, 1998; Colditz, 1999; 
Sander and Bergemann, 2003; Vazquez-Sanchez and Alemany, 2002; Müller-
Riemenschneider et al., 2008), while others make estimates relying on representative sample 
data (Finkelstein et al., 2004; Arterburn et al., 2005). These studies report that the proportion 
of national health care expenditure attributable to obesity ranges from 5.3 to 7% for the US 
and from 0.7 to 2.6% in other countries. In Spain, the share is reported to reach 7% of total 
health care expenditure.1 A second set of studies takes a lifetime perspective and employs 
medical records in order to estimate the impact of BMI categories on resource utilisation and 
direct costs. Most are based on US data (Quesenberry et al., 1998; Thompson et al., 2001; 
Raebel et al., 2004; Finkelstein et al., 2005; Wee et al., 2005) and very few on data from other 
countries (Borg et al., 2005; Nakamura et al., 2007; van Baal et al., 2008). 
The study we report here is conducted in line with this second set of studies. But while 
we employ microdata and take a longitudinal perspective, the methods adopted differ 
significantly. We specifically apply panel data methods which have been widely recognised in 
                                                 
1
 Among studies of this type, a number estimate medical costs and obesity based on survey data (Sturm, 2002; 
Andreyeva et al., 2004; Von Lengerke et al., 2006). 
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the literature on the estimation and prediction of healthcare expenditure using cross-section 
data. Namely, our paper is methodologically similar to those of Cawley and Meyerhoefer 
(2012) and Wolfenstetter (2012), although their estimations of the medical costs of obesity 
and overweight rely on cross-section data.2 
 
3. Empirical Methods 
 
3.1 The Two-Part Model 
 
We model the increase in medical costs associated to obesity and overweight using a “two-
part model” (2PM). This strategy has been widely used for analysing outcomes with a large 
proportion of zero observations (non-users), a strongly skewed distribution as well as a long 
right-hand tail of individuals who make a heavy use of healthcare resources (Manning et al., 
1981; Duan et al., 1983; Duan et al., 1984).3 
Specifically, the first part of the 2PM is estimated using a random effects (RE) logit 
binary regression model and the second part is specified as a Generalised Linear Model 
(GLM) panel regression of (positive) direct medical costs on a set of controls.4 GLM has 
become a dominant strategy to modelling healthcare costs when there are unknown forms of 
heteroskedasticity (Mullahy, 1998; Manning and Mullahy, 2001; Buntin and Zaslavsky 2004; 
Manning et al. 2005, Manning, 2006).5 Since GLM estimates are performed on the raw 
medical cost scale, there is no need for retransformation. In addition this approach allows for 
heteroskedasticity through the choice of the distribution function. We calculated Pregibon’s 
link test and the Park (1966) test to determine which specific link and distribution functions 
best fits the data, respectively. However, the most frequently used GLM specifications in 
healthcare cost studies are the log link function and the Gamma distribution (Manning and 
Mullahy, 2001; Manning et al., 2005). Note that although GLM is recommended, Manning 
and Mullahy (2001) point out that GLM estimation suffers a substantial loss in precision in 
the face of heavy-tailed, log scale residuals or when the variance function is misspecified 
                                                 
2
 This is the first paper to estimate the (causal) impact of obesity on medical costs using the MEPS 2000-2005 
data and applying the aforementioned methods in health econometrics. 
3
 In our dataset medical costs are zero for 16% of the sample and positive medical costs are highly skewed to the 
right. 
4
 Both equations of the 2PM are estimated by RE (the errors are normal distributed and uncorrelated with the 
regressors) due to the unfeasibility of estimating GLM models by fixed effects. 
5
 We have certainly detected the presence of heteroskedasticity in our dataset by means of the Breusch-Pagan 
and White tests, produced by several covariates, some of which are continuous (i.e., complex heteroskedasticity). 
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(Buntin and Zaslavsky, 2004; Baser, 2007).6 Notice that when we compute the incremental 
effect (IE) of obesity and overweight or the marginal effect (ME) of the BMI regressor on 
medical costs we take into account that this is not as straightforward as it is in linear 
regression models (Hertz, 2010). 
 
3.2 Alternative Empirical Models 
 
Two alternative models are however examined as a robustness exercise. On the one hand we 
estimate a single equation FE linear regression model on the logarithm of medical costs, 
reducing the degree of skewness and kurtosis and making the distribution more symmetric 
and closer to normality.7 Notice that under this approach zero cost observations are left apart 
if one considers that this problem is not too significant.8 Here the computation of the IE (ME) 
of obesity and overweight (BMI) on costs takes into account the heteroskedasticity-adjusted 
retransformation procedure suggested by Mullahy (1998). On the other hand, we estimate a 
sample selection model (SSM) once we assume that the independence hypothesis imposed by 
a 2PM (i.e., the error terms of the two parts are independent of each other) may be a strong 
assumption under a longitudinal context (Cameron and Trivedi, 2005; Albouy et al, 2010). 
Even including an extensive set of controls it is conceivable that those with positive 
expenditure levels may not be randomly drawn from the population (i.e., selection may 
depend on unobserved effects) and the results of the second stage regression suffer from bias. 
As a result, we estimate direct medical costs by means of a panel data SSM, using the 
selection correction procedure proposed by Wooldridge (2010).9 
 
3.3 Some Econometric Challenges 
 
                                                 
6
 A finding that emerges from the literature that compares the performance of several models for positive 
expenditures in terms of consistency and precision (Manning and Mullahy, 2001; Buntin and Zaslavsky, 2004; 
Manning et al., 2005; Baser, 2007; Hill and Miller, 2010) is that no one method dominates the other and there 
are important trade-offs in terms of precision and bias, mainly when different subgroups of population or types 
of medical costs are analysed (Hill and Miller, 2010; Jones, 2010). Notwithstanding, Mihaylova et al. (2011) 
literature review confirms that 2PM models perform better. 
7
 Estimates based on logged models are actually often much more precise and robust than direct analyses of the 
unlogged original dependent variable (Manning, 1998). They may also reduce (but not eliminate) 
heteroskedasticity. 
8
 This is not our particular view and for this reason our central analytical framework is a 2PM. 
9
 Wooldridge (2010) proposed to run a robust probit estimation of not having positive costs for each period t and 
then save the inverse Mill’s ratios. These were later added to the second equation estimated using a RE GLM 
model. We bootstrapped these procedures. Statistical significance of almost all these Mill’s ratios denoted the 
presence of sample selection bias. Likewise, given that the Mills ratio is not strictly exogenous and causes a 
problem of multicollinearity, we introduced exclusion restrictions to greatly reduce these inconveniences. 
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Some econometric challenges posed by our panel data were considered in the estimations. 
First, a patient’s weight and height are not always measured when visiting the doctor, which 
means that for a subset of individuals their BMI may present a missing value in time t. To 
deal with this problem, we restricted the sample to those individuals who had at least one 
weight and height measurement. Based on this information we were able to infer the 
individuals’ BMI for the period 2004-2010.10 Second, since not having weight and height 
measurement information may induce sample selection bias, we followed Wooldridge’s 
(2005) proposal to accommodate this impact. In other words, we ran a robust probit 
estimation of not having covariate measurements for each period t and then saved the inverse 
Mill’s ratios. These were later added to the regression equations. 
Third, under RE estimation we allow for the possibility that the observed BMI (when 
this is the regressor of interest) may be correlated with the time-invariant and individual-
specific effect (αi).11 However, here we followed the Mundlak (1978) procedure which uses 
within-individual means of the BMI rather than separate values for each year. As a 
consequence, the original set of regressors is augmented with the global BMI mean. Fourth, to 
further control for heterogeneity we considered the impact of the previous year’s obesity 
categories (or BMI) on our regressions. Notice that although some endogenous effects may 
still be present (a health status shock via an accident or a job loss) with a marked impact on 
medical spending we assumed that no other effects at the individual level could be controlled 
for. 
Fifth, we also examined a dynamic panel regression specification by including the 
medical costs incurred in the previous year as an additional regressor to capture state 
dependence. To deal with the initial conditions problem, we followed Albouy et al. (2010) 
proposal which modifies Wooldridge’s (2005) approach. In fact, these authors proposed using 
the generalised residual of a simple model in cross-section at the initial date but taking into 
account the two-part model framework. The latter can be considered the best available 
estimation of the over or under propensity to consume health resources at the initial date. 
Sixth, a further sample selection issue of concern occurs if during the analysed period 
individuals drop out from the panel because of immigration, incapacity, death, etc. We found 
that around 3% of our total observations suffered attrition as a consequence of death. Here, 
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 A definition of BMI including patients with three or more measurements was also examined, highlighting a 
potential trade-off between accuracy of BMI definition and sample selection issues. 
11
 In line with Chamberlain (1980), one option could be to assume that 
2
´  (0, )i i iBMI u idd Nα α σ= + : where BMIi = (BMIi1,..,BMIiT) are the values of the BMI for every year of 
the panel, and α = (α1,....., αT). 
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the strategy adopted involved simply including a dummy on the occurrence of death rather 
than including an additional probability of individuals’ dropping out from the panel. Finally, 
the IE and ME were computed manually as a consequence of having transformed data and 
were conveniently bootstrapped. 
 
4. Data and variables 
 
Panel and individual level data of the type required by the empirical analysis followed in this 
paper is simply not available for the whole Spain. As an alternative, we use observational and 
longitudinal data drawn from administrative and medical records of patients followed up over 
seven consecutive years in six primary care centres (Apenins-Montigalà, Morera-Pomar, 
Montgat-Tiana, Nova Lloreda, Progrés-Raval and Marti i Julià) and two reference hospitals 
(Hospital Municipal de Badalona and Hospital Universitari Germans Trias i Pujol), in the 
north-eastern sector of Barcelona serving more than 104,000 inhabitants. This sample of users 
is mostly urban, of lower-middle socioeconomic status from a predominantly industrial area. 
Our sample includes patients aged 16+ who had at least one contact with the healthcare 
system between 1 January 2004 and 31 December 2010, and who were assigned to one of the 
aforementioned healthcare centres during this period.12 The study also considers those who 
died during the period analysed. However, we exclude subjects that were transferred or who 
moved to other centres and patients from other areas or regions.13 
The information used is gathered from a small but representative set of health care 
centres from a country (Spain) organised under a fully funded and decentralised (at the 
regional level) NHS system predominantly within the public sector. Provision is free of 
charge at the point of delivery with the exception of pharmaceuticals entailing some 
copayments. 
This dataset incorporates a rich set of information about the individual patients’ use of 
healthcare resources (including, number of visits to the GP; specialist and emergency care; 
number of hospitalizations and bed days; laboratory, radiology and other diagnostic tests; and 
consumption of medicines), their clinical measurements of height and weight, and each 
patient’s chronic conditions and other diagnosed diseases (according to the ICPC-2), any 
                                                 
12
 The sample contains observations with zero medical costs because there are individuals who contacted –at 
some point during the analysed period– the health system and incurred in positives costs, but in other years have 
zero costs. 
13
 Although we have a sample of users, they are almost the entire population representing 96.52% of total 
residents in the specific considered geographic area. The NHS nature of the Spanish health care system may 
explain why we observe this high percentage during a consecutive period of seven years. 
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functional limitations, their date of admission and discharge, type of healthcare 
professional(s) contacted and the motive of their visit. Moreover, the dataset includes details 
of each patient’s age, gender, employment status (active/retired), place of birth and habitual 
residence. 
Owing to a unique identifier, the data from the administrative and medical records can 
be merged with the Population Census allowing us to incorporate new variables for each 
patient (e.g., education or marital status) not available in the original sample. 
 
4.1 Data on Healthcare Costs 
 
In addition to its longitudinal nature, the dataset provides a wide array of information on 
healthcare costs. This includes the specific characteristics of the primary and hospital 
healthcare centres considered and also the extent of development of their information 
systems. In addition to these internal sources, costs were also calculated (where necessary) 
using data taken from invoices for intermediate products issued by a number of different 
providers and from the prices fixed by the Catalan Health Service. 
The computation of healthcare costs follows a two-stage procedure: first, incurred 
expenditures (financial accounting) are converted into costs (analytical accounting), which are 
then allocated and classified accordingly.14 Depending on the volume of activity, we consider 
two types of costs: fixed or semi-fixed costs and variable costs. The former include personnel 
(wages and salaries, indemnifications and social security contributions paid by the health 
centre), consumption of goods (intermediate products, health material and instruments), 
expenditures related to external services (cleaning and laundry), structure (building repair and 
conservation, clothes, and office material) and management of healthcare centres, according 
to the Spanish General Accounting Plan for Healthcare Centres. The latter include costs 
related to diagnostic and therapeutic tests and pharmaceutical consumption.15  
Our unit of measurement is the cost per treated patient during the period in which the 
subject was observed and all the direct cost concepts imputed for the set of diagnosed 
episodes. Table 1 presents our estimates of the resulting unitary cost rates for the years 2004 
and 2010. As such, the total medical costs per patient in each period are calculated as the sum 
                                                 
14
 Expenditures not directly related to care (e.g. financial spending, losses due to fixed assets, etc.) were 
excluded from the analysis. 
15
 For instance we considered: (i) laboratory tests (haematology, biochemistry, serology and microbiology), (ii) 
conventional radiology (plain film requests, contrast radiology, ultrasound scans, mammograms and 
radiographs), (iii) complementary tests (endoscopy, electromyography, spirometry, CT, densitometry, perimetry, 
stress testing, echocardiography, etc.); iv) pharmaceutical prescriptions (acute, chronic or on demand). 
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of fixed and semi-fixed costs (i.e., average cost per medical visit multiplied by the number of 
medical visits) and variable costs (i.e., average cost per test requested multiplied by the 
number of tests + retail price per package at the time of prescription multiplied by the number 
of prescriptions). Note that in this study we do not account for the computation of ‘out-of-
pocket payments’ paid by the patient or family, as they are not registered in the database. 
Healthcare costs figures were converted to 2010 Euros using the Consumer Price Index (CPI). 
 
[Insert Table 1 around here] 
 
4.2 Other variables 
 
The body mass index (BMI) of each patient was calculated as weight (in kilograms) divided 
by the square of height (in metres) using clinical or measured information. Notice that in our 
sample not all patients were measured when they visited the physician; however, others were 
measured on more than one occasion. We tried to account for this specific problem as 
previously mentioned. Obesity and overweight conditions were calculated by using the 
following WHO classification that distinguishes between normal-weight (18 ≤ BMI < 25 
kg/m2), overweight (25 ≤ BMI < 30 kg/m2), moderate (class I) obesity (30 ≤ BMI < 35 kg/m2) 
and severe (class II) obesity (BMI of ≥ 35 kg/m2). The obesity category was subdivided since 
the costs of excess weight come mainly from heavier individuals.16 The influence of the 
continuous BMI regressor on medical costs was also examined. 
To identify the impact of obesity and overweight (or, alternatively BMI) on medical 
costs we included a wide range of covariates. First, we controlled by the patients’ 
demographic characteristics, including age and gender, and also by immigrant status, since 
there is evidence that the immigrant population presents a different pattern of use and access 
to healthcare services. Note that non-linear age effects were considered after running the 
modified Hosmer-Lemeshow test. We also added a set of dummies to control for their 
employment status (active/retired), lifestyles (smoking and alcohol consumption), whether the 
individual was the main beneficiary of the public health insurance, and whether Catalan was 
their usual language of communication. Importantly, since under a clinical point of view it 
can be very difficult to isolate non-obesity related medical conditions, our econometric 
                                                 
16
 Although the BMI is the most widely used measure of obesity, it is not free of problems. For instance, the 
BMI does not take into consideration body composition (adiposity vs. lean weight) or body fat distribution. This 
means it may fail to predict obesity among very muscular individuals and the elderly. 
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specifications will not control for any specific disease. However, as a robustness check we 
will examine how results are changed when some conditions unconnected (in principle) with 
obesity and overweight are controlled for. Merging these data with the Population Census 
allowed us to control medical costs by the patients’ educational level and marital status. 
We have an initial unbalanced panel dataset containing 706,473 observations for the 
whole period 2004-2010. However, when we restrict the sample to patients presenting at least 
one weight and height measurement, the final sample is reduced to 452,108 observations 
(64%).17 
 
5. Results 
 
5.1 Summary Statistics 
 
Descriptive statistics for the main set of variables used in the empirical exercise are presented 
in Tables 2-4. Table 2 shows that the mean annual total medical costs per patient for the 
period 2004-2010 is 755.11€ (in 2010 Euros), which is considerably higher than the median 
of 306.92€ (less than half that of the mean cost in our final sample). The skewness statistic 
(5.91 compared to 0 for symmetric data) and the kurtosis coefficient (82.97 compared to 3 for 
normal data) indicate that the distribution of costs in levels is highly skewed to the right. As 
expected, the logarithmic transformation reduces the range of variation of costs, narrowing 
the degree of skewness: the mean medical cost (6.01€) approximates to that of the median 
(6.09€) and the skewness (kurtosis) statistic falls to -0.23 (2.66). Although not shown, mean 
(median) annual medical costs in the initial sample amounts to 544.04€ (139.93€).18 
 
[Table 2 around here] 
 
Direct medical costs are zero for 16.4% of the sample (74,144 obs.) while the number of 
observations with positive medical costs is 377,964. As Table 3 shows, mean positive annual 
costs per patient reaches 903.09€. This figure is significantly higher for women (949.40€) 
                                                 
17
 Of course, a much more reduced sample is obtained (around 80,000 observations) when individuals with 3 or 
more anthropometric measurements are considered. 
18
 Interestingly, a roughly 40% of the observations without BMI measurements are immigrants. This particularity 
may help to explain why they are less measured. As they are younger, have less medical episodes and less 
severity, medical expenditures in the final sample are relatively larger. 
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than it is for men (845.96€). As expected, medical costs increase with patients’ age, with a 
higher Charlson comorbidity index and with terminal illness. 
 
[Table 3 around here] 
 
Finally, Table 4 summarises the mean and standard deviation values of the variables of 
interest and of the controls. In our sample, the mean BMI in the period of study is 26.70, 
corresponding to a prevalence of moderate (class I) obesity (overweight) of 23% (36%). As 
expected, the mean measured BMI is slightly higher among men (26.75) than it is among 
women (26.67), with the prevalence of class I obesity being higher among women (25% vs. 
21%) and overweight among men (42% vs. 31%). Severe (class II) obesity is also much more 
prevalent among women (8.7%) than among men (4.4%) in our dataset. This differential 
pattern of prevalence rates by gender is also observed for the US, although at a lower level. 
Notice that women represent 54% of the sample and that they are slightly older than men 
(48.86 vs. 47.52 years of age). Note that as we are using a sample of users aged 16+, this 
average age (48) is higher than the average age for the entire Spanish population (41 in 2011), 
which means that we are using a skewed sample of users towards older ages. 
Notwithstanding, if we included the non-adult group of users our sample average age is 42.9. 
Differences by gender are also found with respect to smoking (28% M vs. 17% W) and 
alcohol (3.5% vs. 0.4%) behaviours and public health insurance (95% vs. 82%), closely 
related to the higher participation of men in the labour market. As for labour status, around 
67% of the sample is active and the percentage of individuals who have to be dropped from 
the sample due to death is higher among men (3% vs. 2%). 
 
[Table 4 around here] 
 
5.2 Obesity, Overweight and Direct Medical Costs 
 
In Tables 5-8 we present the results of our panel data estimations. Specifically, these tables 
show the bootstrapped estimates of the incremental effects (IEs) of the patients’ measured 
obesity types and overweight on total medical costs. Alternatively, the bootstrapped marginal 
effects (MEs) are calculated when BMI is the regressor of interest. Accompanying these 
estimates, we also report measures of goodness of fit and of the predictive performance for 
each model (i.e., the auxiliary R2, the root mean square error – RMSE, and the mean absolute 
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prediction error – MAPE). Note that these estimations account for a wide list of controls (see 
Section 4.2), health district dummies and time dummy variables. In addition, as discussed 
previously, each model incorporates the inverse Mill’s ratio of not having weight and height 
measurements, the global mean BMI or the Mundlak correction procedure (when needed), 
one-year lagged class I and II obesity and overweight rates (or measured BMI) and a dummy 
for the occurrence of death. The number of bootstrap replications is set at 200. 
The first set of results in Table 5 presents the IEs or the increase in annual direct 
medical costs of severe obesity, moderate obesity and overweight using a 2PM approach. 
Notice that the first part of the 2PM specifies a panel data probit model to estimate positive 
medical costs while the second part uses GLM panel data regression based on a Gamma 
distribution with the log link function (widely used in the literature on health care costs).19 
Two econometric specifications are examined. According to the first specification (section 
5.A) and the static version, we find a positive and statistically significant (at 1%) moderate 
obesity and overweight impacts on medical costs. Namely, compared with normal-weight 
individuals becoming moderately obese raises direct medical costs by 109.30€ per patient and 
year. As expected the impact of the overweight status on such costs is notably lower (46.85€). 
Under the dynamic version (where we include a one period lag dependent variable in both 
equations of the 2PM) the IEs of both moderate obesity and overweight on costs is slightly 
stronger (115.37€ and 56.04€, respectively). Interestingly, a relatively better performance is 
achieved using the latter model compared to the non-dynamic version.  
 
[Table 5 around here] 
 
According to the second specification (section 5.B) where the obesity category is further 
subdivided and the dynamic version is used, we find, as expected, a much stronger impact of 
severe obesity on medical costs compared to moderate obesity. Certainly, severely 
(moderately) obese individuals raise medical costs by an amount of 161.85€ (99.81€) per 
patient and year; whereas overweight raises medical costs by roughly 52€ per patient 
annually. In other terms, with total medical costs averaging 600€ for normal-weight 
individuals, the estimated extra annual costs of severe obesity correspond to a 27% increase, 
for moderate obesity to a 17% increase, and for overweight to a 9% increase. 
                                                 
19
 The Pregibon link test gives an estimated value of -0.591*10-5 (p-value=0.000) which is practically 0, 
suggesting the logarithm as the link function. The Park (1966) test gives a coefficient 1.79υ =  (p-value=0.000) 
which is consistent with a Gamma-class distribution. 
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Although not shown, the GLM model performs much better than the OLS log costs estimation 
using a 2PM as long as the RMSE and MAPE (auxiliary R2) measures decrease (increase) 
substantially.20  
 
5.3 Impact of Obesity by Groups 
 
To assess how the above estimations vary with respect to different sample groups, Table 6 
presents the IEs of the two obesity classes and overweight differentiating by gender and age, 
given the evidence of a marked differentiated pattern in the utilization of healthcare resources 
by these two populations in most western countries. The reference approach is again the 2PM 
GLM model with the dynamic version given its superior comparative fit. This set of new 
estimates includes the same controls as those accounted for in the previous tables. 
Interestingly, we find that the increase in medical costs per patient and year associated with 
these conditions is more powerful among women (W) than among men (M). Specifically, 
severe obesity raises medical costs by 170.07€ (W) vs. 145.64€ (M); moderate obesity raises 
costs by 115.83€ (W) vs. 84.61€ (M) and overweight raise costs by 60.73€ (W) vs. 43.49€ 
(M). In terms of relative changes, once the average costs of normal-weight individuals for 
both men and women are taken into account, severely (moderately) obese women raise 
medical costs by 29% (19.5%); whereas severely (moderate) obese men increase costs by just 
24% (14%). 
A similar picture emerges when the sample is split by age. Severe obesity has a larger 
effect on medical costs in absolute terms among those aged above the median age of 42 
(209.90€) than those aged below (87.34€). However, the relative rise was slightly higher 
among the younger subgroup (25% vs. 21.5%). The same is true for moderate obesity and 
overweight.  
 
[Table 6 around here] 
 
5.4 A Robustness Analysis  
 
                                                 
20
 These results can be provided by the authors upon request. 
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Table 7 is devoted to present some robustness analysis. Instead of assessing the impact of 
BMI categories, Section 7.A shows the estimated effect of measured BMI on healthcare costs. 
We report the bootstrapped marginal effect (ME) of BMI on direct medical costs using a 2PM 
with a GLM procedure for the second part based on a Gamma distribution and the log link 
function. Notice that we included here the Mundlak correction procedure and the one-year 
lagged BMI regressor, when the rest of the econometric issues posed by the data set were 
accounted for. As expected, our results show a highly significant and positive estimated ME 
of BMI on medical costs. Under the “static” version we find that one additional unit of BMI 
(or 2.7 kg. weight increase) results in an increase of 11.62€ in average total medical costs per 
patient and year. Under the dynamic version, a slightly lower marginal influence on mean 
annual costs is found (10.40€) when the individual’s BMI rises in one unit. Again, the 
accuracy and goodness of fit achieved with this latter estimation is greater, in terms of lower 
RMSE and MAPE and higher auxiliary R2. 
 
[Table 7 around here] 
 
In order to check the sensitivity of the above results based on the 2PM framework, two 
alternative methodological approaches are examined (section 7.B). This analysis is performed 
using individual BMI as the variable of interest, which allows us to compare estimations 
easily. The first row shows the impact of BMI via the estimation of a single equation FE 
linear regression model of the logarithm of medical costs, using the sample of patients who 
incurred in positive costs. Clearly, this strategy leaves apart the zero observations problem. 
However, a heteroskedasticity-adjusted retransformation procedure was applied in the 
estimation of the ME of BMI. This need was evidenced by the following tests. On the one 
hand, the Shapiro-Wilk test rejected the null hypothesis that the log residuals were normally 
distributed (W=18.13, p-value=0.000). On the other hand, evidence of heteroskedasticity was 
found when regressing the squared residuals of log costs on a set of covariates (Chi-
squared=1.18*106, p-value=0.000). A variant of the Park test suggested that several covariates 
contributed to this heteroskedasticity. Therefore, according to the dynamic version of this 
model, we find that one additional unit of BMI (or 2.7 kg. weight increase) results in a raise 
of 6.73€ in annual total medical costs per patient, which is clearly lower than the impact 
computed through the 2PM framework (10.40€). Notice this alternative model is much poorer 
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in terms of goodness of fit and predictive capacity.21 This finding is compatible with Hill and 
Miller (2010) that sustain that OLS of log (costs) models tend to perform poorly in terms of 
their bias and predictive accuracy, making the GLM more attractive for the second part of the 
two-part model. Cawley and Meyerhoefer (2012) follow the same strategy when estimating 
their models. 
The second row of section 7.B presents the estimation of direct medical costs using a 
panel data sample selection approach (SSM), following the selection correction procedure 
suggested by Wooldridge (2010). As previously mentioned, the set of IMRs obtained from a 
robust probit estimation of not having positive costs for each period t are added in the 
estimation of a RE GLM model (with log link and Gamma distribution). The exclusion 
restrictions are labour status, public insurance coverage and immigrant status. The dynamic 
version of this SSM shows again a positive and significant ME of BMI on medical costs 
(11.20€) which is roughly similar to the effect computed using the 2PM approach.22 However, 
in our data the IMRs are statistically significant at 10% just in 2 out of the 7 years analysed. 
Additionally, we follow the test of independence of the two error terms suggested by Albouy 
et al. (2010) and we cannot reject the null assumption. On the basis of these findings, the 
central estimates of the impact on medical costs will be based in this paper on the 2PM 
framework. 
 Finally, the last part of Table 7 (section 7.C) analyse, under a 2PM approach, how 
sensitive the impact of BMI is when certain patients’ conditions are included and another 
sample is used. Specifically, in the first row we estimate the ME of BMI when some non-
related-obesity conditions (e.g., asthma, COPD, psychosis, dementia, cancer) are added as 
controls in the specification. Interestingly, the dynamic version predicts a significant but 
notably lower ME of BMI on medical costs compared to our central model estimate of Table 
6 (4.71€ vs. 10.40€). We interpret this evidence as indicating that part of the variation in 
medical costs, previously attributed to the individuals’ body mass, is now captured by such 
health conditions. However this finding would suggest that there are not really unrelated 
(chronic) obesity conditions and in some way or another they are connected, indirectly 
supporting the decision to exclude all of them to gather the real impact of obesity (BMI) on 
medical costs. The last row in section 7.C assesses the increase in medical costs when we 
                                                 
21
 Although not shown, an even worst fit is obtained when we apply the same method on raw (unlogged) medical 
costs. 
22
 If we instead specify a log cost model for the second part of the sample selection model -following Albouy et 
al, 2010- and apply FE estimation we obtain a slightly lower significant ME coefficient. Note that this alternative 
model shows a greater RMSE value. 
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adopt a stricter definition of BMI, i.e., including patients with three or more measurements. 
Interestingly, we find that this measurement of BMI increases medical costs (10.22€) in a 
similar magnitude that the one adopted in section 7.A when BMI is defined considering at 
least one weight and height measurement. Therefore, it seems that the estimation is not 
affected by the trade-off between accuracy of the BMI measure (given the presence of 
missing values) and the sample selection problem. 
 
5.5 IV estimation by means of biological information 
 
One could argue that medical costs and severe/moderate obesity or overweight may have an 
endogenous relationship. This is the case if patients who incur in higher utilization of 
healthcare resources and costs also experience a change in their bodyweight caused, for 
instance, by psychological factors or other diseases (e.g., cancer, dementia, and other 
cachexia-inducing ailments). To overcome this problem and derive a causal effect on medical 
costs, we followed Davey Smith et al. (2009) and Cawley and Meyerhoefer (2012) proposal 
and instrumented the individuals’ severe obesity, moderate obesity and overweight rates with 
the prevalence rates of a biological relative (i.e., children’s information).23 The validity of this 
instrument is firstly based on the fact than children and parent’s obesity (BMI) are closely 
related not only on genetic grounds but, more importantly, as a consequence of a proven inter-
temporal transmission of values and lifestyles. Secondly, we assume that the instrument is 
uncorrelated with the error term of the equation of medical costs and with confounding 
factors. Contrary to Cawley and Meyerhoefer (2012) our weight and height data are clinically 
measured and, as such, the BMI does not suffer any misreporting and use longitudinal 
information to control for unobserved heterogeneity. Moreover, as long as various primary 
care programs (i.e., the Healthy Child Program) specifically targeted children, we have 
considerably more information on children’s BMI to construct the instrument than was the 
case in Cawley and Meyerhoefer’s (2012) study. We considered non-linearities in the 
instrument (quadratic and cubic terms). 
Table 8 reports the IV estimates of the incremental effects (IEs) on medical costs 
assuming a 2PM-GLM dynamic version model. For comparative purposes the first row shows 
the non-IV IEs of the two obesity classes and overweight using the same sample size as that 
used under the IV estimation, which of course is greatly reduced as only individuals with 
                                                 
23
 Given that we linked our dataset to census information we were able to obtain household and parental 
identifiers. 
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children are considered. Our findings indicate that the IV estimates of the causal influence of 
the BMI categories on direct costs are larger than those without instrumenting. Once we purge 
by the reverse causality problem we end up with a more powerful influence on medical costs. 
In particular, the results show that patients with severe obesity cause an increase in direct 
medical costs of 206.48€ (34% increase) per patient and year, with moderate obesity by 
174.69€ (29% increase) and with overweight by 136.02€ (23% increase).24 
 
[Table 8 around here] 
 
Notwithstanding, these IV estimations should be taken with some caution as we may have a 
rather weak instrument. Notice that the use of family's characteristics as instruments may be 
problematic, for example, as individuals may decide to seek more medical care (medical 
treatments and diagnostic tests) when they hear about family members' illnesses, especially if 
these illnesses have a genetic component. Even if they don't have a genetic component, people 
may become more aware of different types of illnesses when their family members get ill. 
 
6. Conclusion 
 
This study has examined the association (and causal impact)  of obesity and overweight with 
the increase of direct medical costs using a two-part model as a central approach and a 
longitudinal dataset of administrative and medical records of patients followed up over seven 
consecutive years (2004-2010) in Spain. This is the first application in the literature of this 
methodology based on longitudinal information and BMI measurements as opposed to self-
reported data. 
Obesity is related with an important number of chronic (for the rest of life) diseases 
affecting the health status and quality of life of patients. One clear consequence of obesity is 
the higher health care costs borne by the entire society (i.e., negative externality) through 
higher insurance premiums or taxes to cover the extra funding. Hence, understanding the link 
between body mass or obesity and medical costs should be then crucial to achieve a more 
sustainable growth of health expending; especially at a time of increased pressure to cut 
successively public budgets. It should also serve as a way to stimulate the allocation of more 
resources into prevention actions to tackle the development of the epidemic. 
                                                 
24
 Note that these results provide an estimate of the Local Average Treatment Effect (LATE) of being obese or 
overweight on medical costs for a sample of individuals with children. 
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The results indicate that obesity is associated with substantial healthcare costs 
increases and there are large differences in costs by degree of obesity. Specifically, severe 
obesity raises total direct medical costs by an average of 160€ per patient and year. With total 
medical costs averaging 600€ for normal-weight individuals, this means that severe obesity is 
associated with an increase in costs of 26%. The effect of moderate obesity is more modest: it 
raises medical costs by 97€ or 16% increase. Overweight has an even smaller impact raising 
costs by 51€ or 8.5% increase. This evidence shows that the burden imposed on the health 
care system by these conditions grows large for the most obese segment of the Spanish 
population. 
The relative changes in medical costs are slightly higher for those patients below the 
median age and for the women. Severe (moderate) obesity raises medical costs around 29% 
(19.5%) in case of women and just 24% (14%) in case of men. Alternatively, severe 
(moderate) obesity increase costs by 21% (12%) for those aged above the median age of 42 
but 25% (18%) for those younger than this threshold. This latter finding would be compatible 
with other results indicating a weak association between high BMI levels and adverse health 
outcomes among old-age individuals. 
Our IV estimations predict an even higher (causal) effect of the BMI categories on 
direct costs. Based on the full sample, the results show that patients with severe obesity 
increase medical costs by 206€ (34% increase) per patient and year; moderate obesity by 175€ 
(29% increase) and overweight by 136€ (23% increase). 
To put these estimates in perspective, the costs increases documented in this paper 
compare well with the findings provided, for instance, by Sturm et al. (2013). These authors 
using cross-sectional data of a comprehensive medical scheme in South Africa find that 
severe (moderate) obesity increases annual medical expenditures by 23% (11%) in the year 
2010. However, the estimated impacts on costs are certainly lower than those calculated for 
the US. Finkelstein et al. (2004) combining the MEPS and NHIS datasets for the US find that 
(moderate) obesity is associated with a 37% increase in annual medical spending. Similarly, 
Thorpe et al. (2004) combining other US data show that costs incurred by obese individuals 
(BMI ≥ 30) were 37% higher than costs for those with normal weight in 2001. The impacts of 
bodyweight on mean healthcare costs shown by Cawley and Meyerhoefer (2012) for the US 
or von Lengerke et al. (2010) for Germany are also larger than the effects we find for Spain. 
Again, our estimates are also much more modest when the analysis is restricted to 
individuals aged 54-69 to parallel some US studies (Andreyeva et al., 2004; Sturm et al., 
2013). According to our regressions we find that severe (moderate) obesity is associated with 
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increases in medical costs of 24.5% (14%) for this age group. This is substantially lower to 
the US estimations for the same age group reported by such studies, where severe obesity was 
related with an increase of more than 50% and moderate obesity with an increase of 25%.  
A tentative explanation could be that, in addition of having lower levels of fatness, the 
Spanish healthcare system provides universal coverage and its services are free at the point of 
delivery. Furthermore, during the period of analysis, strict cost-containment policies were in 
operation. These results have important implications for public health policies as they suggest 
that reducing population levels of obesity and overweight (or preventing their rise) will have a 
considerable benefit not only to population health but also on government budgets. Although 
some argue that the onset of obesity-unrelated diseases due to the life-years gained by the 
prevention policies could even offset the gains in costs. 
This paper has several limitations that should be noted. First, the study sample 
includes individuals living in an urban city of Catalonia which makes the extrapolation to the 
entire Spanish population difficult. Second, the sample contains individuals with no BMI 
measurements or observations with zero medical costs. This omission may bias the results 
when a significant share of the individuals with no BMI measurements are immigrants and 
enjoy a relatively better health status. Third, our central estimates do not include controls on 
medical conditions given the complex task of isolating the group of non-obesity related 
medical conditions of the patients. Fourth, as income is not collected in the dataset the 
estimations do not control for this potential confounder of the relationship between BMI 
classes and direct medical costs. Fifth, another limitation is the (weak) validity of the 
instrument based on children’s information. Finally, like the previous literature this paper uses 
BMI as a measure of fatness given the impossibility of using more refined measurements (i.e., 
body fat percentage or waist circumference).  
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Table 1. Unit cost estimates per patient in 2004 and 2010 
Healthcare resources 
Unit costs (€) 
2004 
Unit costs (€) 
 2010 
Medical visits:   
Visits to Primary Medical Care 16.09 24.37 
Visits to Emergency Care 79.49* 123.48 
Hospitalization (per day) 217.03* 337.13 
Visits to Specialist Care 71.30* 110.76 
Complementary tests:   
Laboratory tests 18.33 22.64 
Conventional radiology 14.64 18.79 
Diagnostic/therapeutic tests 21.37 37.76 
Pharmaceutical prescriptions PVP PVP 
Note: Figures for years 2004-2010 are estimated from linear interpolation based on observed data in 2003 and 
2009. Figures for the year 2010 are derived using the same growth rates. (*) These figures were estimated using 
the growth rate experienced by primary care visits during the period 2003-2009. PVP is retail price. 
Source: BSA analytical accounts.  
 
 24 
Table 2. Mean Annual Total Direct Medical Costs per Patient 2004-2010 (in Euros 2010) 
 
 
Final Sample 
 
Costs 
(in Euros) 
Log Costs 
Mean 755.11 6.01 
Median 306.92 6.09 
Standard Deviation 1,309.96 2.55 
   
Skewness 5.91 -0.23 
Kurtosis 82.97 2.66 
N (Number of obs.) 452,108 377,964 
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Table 3. Mean Annual Total Direct Medical Costs per Patient 2004-2010 (in Euros 
2010): Positive costs 
 
 Final Sample with Positive Costs 
 Both Genders Male Female 
Full sample 903.09 (1,382.42) 845.96 (1,378.48) 949.40 (1,383.88) 
  
 By subgroups: 
Ages 16-24 335.29 (425.99) 325.67 (418.85) 344.10 (432.24) 
Ages 24-40 390.40 (607.38) 380.78 (664.52) 398.32 (555.83) 
Ages 40-54 624.72 (852.38) 574.61 (855.90) 664.21 (847.53) 
Ages 54-65 1,049.15 (1,246.88) 974.56 (1,212.95) 1,113.64 (1,271.99) 
Ages + 65 1,911.87 (2,097.58) 1,862.60 (2,167.37) 1,947.54 (2,044.84) 
Active (labour status) 493.28 (678.66) 467.65 (673.02) 515.50 (682.74) 
Charlson index (>0) 1,777.23 (2,057.78) 1,693.65 (1,992.99) 1,863.36 (2,119.18) 
Immigrant status 411.74 (698.34) 383.81 (764.77) 435.35 (635.88) 
Deceased individuals 3,302.33 (4,727.91) 3,411.68 (5,066.23) 3,173.23 (4,292.89) 
N (Number of obs.) 377,964 169,199 208,765 
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Table 4. Descriptive statistics of some control variables. Period 2004-2010 
 
 
Final Sample 
 
Both Genders Male Female 
    
BMI 26.70 (5.18) 26.75 (4.54) 26.67 (5.67) 
Moderate Obesity 0.23 (0.42) 0.21 (0.41) 0.25 (0.43) 
Severe Obesity 0.067 (0.25) 0.044 (0.21) 0.087 (0.28) 
Overweight 0.36 (0.48) 0.42 (0.49) 0.31 (0.46) 
Age 48.24 (19.23) 47.52 (18.84) 48.86 (19.54) 
Female 0.54 (0.50) - - 
Immigrant status 0.05 (0.22) 0.05 (0.23) 0.05 (0.22) 
Active (labour status) 0.67 (0.47) 0.70 (0.46) 0.65 (0.48) 
Alcohol consumption 0.019 (0.14) 0.035 (0.18) 0.004 (0.21) 
Smoking 0.22 (0.42) 0.28 (0.45) 0.17 (0.38) 
Public health insurance 0.88 (0.32) 0.95 (0.21) 0.82 (0.38) 
Catalan language 0.99 (0.09) 0.99 (0.10) 0.99 (0.08) 
Deceased individuals 0.03 (0.17) 0.03 (0.18) 0.02 (0.15) 
N (Number of obs.) 452,108 209,637 242,471 
Note: Figures are mean values between 2004-2010. Standard deviations are reported in parentheses. Moderate 
obesity(30 ≤ BMI ≤ 34.9 kg/m2), Severe obesity (BMI ≥ 35 kg/m2). 
 
 
Table 5. Increase in annual direct medical costs of severe and moderate obesity and 
overweight (in Euros 2010). Panel data estimation 
 
Section 5.A 
Two-Part Model 
IE  
Moderate 
Obesity 
IE 
Overweight RMSE MAPE Auxiliary R2 
GLM “static version” 
(N=373,058) 
109.303 
(5.43)*** 
46.852 
(3.36)*** 214,806 466.51 0.485 
GLM “dynamic version” 
(N=258,900) 
115.371 
(5.92)*** 
56.044 
(6.73)*** 174,374 460.17 0.573 
 
Section 5.B 
Two-Part Model 
IE  
Severe 
Obesity 
IE  
Moderate 
Obesity 
IE 
Overweight RMSE MAPE Auxiliary R2 
GLM “dynamic version” 
(N=258,900) 
161.850 
(7.01)*** 
99.812 
(6.21)*** 
52.002 
(6.68)*** 174,296 459.96 0.573 
Notes: IE stands for incremental effect. Severe obesity: BMI≥35 kg/m2; moderate obesity: 30≤BMI<35 kg/m2; 
overweight: 25≤BMI<30 kg/m2; normal weight (reference category): 18.5≤BMI<25 kg/m2. Auxiliary R2 denotes 
the R-squared from a regression of actual costs on the predicted values; RMSE denotes the root mean squared 
error; MAPE is the mean absolute prediction error. Estimations account for an extensive list of covariates, health 
district dummies and time dummy variables. Regressions contain one-year lagged obesity/overweight rates. IEs 
have been bootstrapped (number of replications set at 200). N sample units refers to the second part. ***p<0.01; 
**p<0.05; *p<0.10 
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Table 6. Increase in annual direct medical costs of severe and moderate obesity and 
overweight by gender and age (in Euros 2010). Panel data estimation 
 
Two-Part Model IE Severe Obesity 
IE Moderate 
Obesity 
IE 
Overweight RMSE MAPE 
Auxiliary 
R2 
GLM “dynamic version”. 
Men sample (N= 115,613) 
145.64 
(9.42)*** 
84.61 
(8.01)*** 
43.49 
(7.34)*** 115,958 457.55 0.563 
GLM “dynamic version” 
Women sample (N=147,038) 
170.07 
(13.51)*** 
115.83 
(10.18)*** 
60.73 
(11.59)*** 130,188 462.64 0.570 
GLM “dynamic version” 
Below median age (42) 
(N=118,180) 
87.34 
(16.07)*** 
63.79 
(10.41)*** 
31.74 
(6.04)*** 67,541 281.31 0.383 
GLM “dynamic version” 
Above median age (42) 
(N=124,231) 
209.90 
(15.95)*** 
118.10 
(11.15)*** 
52.31 
(9.45)*** 166,212 565.36 0.572 
Notes: IE stands for incremental effect. Severe obesity: BMI≥35 kg/m2; moderate obesity: 30≤BMI<35 kg/m2; 
overweight: 25≤BMI<30 kg/m2; normal weight (reference category): 18.5≤BMI<25 kg/m2. Auxiliary R2 denotes 
the R-squared from a regression of actual costs on the predicted values; RMSE denotes the root mean squared 
error; MAPE is the mean absolute prediction error. Estimations account for an extensive list of covariates, health 
district dummies and time dummy variables. Regressions contain one-year lagged obesity/overweight rates. IEs 
have been bootstrapped (number of replications set at 200). N sample units refers to the second part. ***p<0.01; 
**p<0.05; *p<0.10 
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Table 7. A robustness analysis: the increase in annual direct medical costs associated 
with (measured) BMI (in Euros 2010). Panel data estimation 
 
Section 7.A 
Two-Part Model ME of BMI RMSE MAPE Auxiliary R2 
GLM “static version” (N=318,276) 11.622 (1.09)*** 333,482 457.39 0.534 
GLM “dynamic version” (N=258,900) 10.404 (2.06)*** 257,508 501.13 0.627 
 
Section 7.B 
Models ME of BMI RMSE MAPE Auxiliary R2 
Single Equation Model  
FE OLS log(costs) “dynamic version” 
(N=318,276) 
6.733 (1.33)*** 836,377 1,641.32 0.329 
Sample Selection Model  
GLM “dynamic version” (N=258,900) 11.203 (1.40)*** 310,557 540.61 0.539 
 
Section 7.C 
Two-Part Model ME of BMI RMSE MAPE Auxiliary R2 
GLM “dynamic version” 
Obesity unrelated diseases (N=258,900) 4.714 (1.94)*** 257,187 500.28 0.621 
GLM “dynamic version” 
3+ BMI measurements (N=67,594) 10.224 (2.64)*** 177,018 557.56 0.490 
Notes: ME stands for marginal effect. Auxiliary R2 denotes the R-squared from a regression of actual costs on 
the predicted values; RMSE denotes the root mean squared error; MAPE is the mean absolute prediction error. 
Estimations account for an extensive list of covariates, health district dummies and time dummy variables. MEs 
have been bootstrapped (number of replications set at 200). All regressions contain one-year lagged measured 
BMI. The Mundlak correction procedure is applied (with exception of the first model in Section 7.B). 
***p<0.01; **p<0.05; *p<0.10 
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Table 8. IV estimates: increase in annual direct medical costs of severe and moderate 
obesity and overweight (in Euros 2010). Panel data estimation 
 
Two-Part Model 
IE 
Severe 
Obesity 
IE Moderate 
Obesity 
IE 
Overweight RMSE MAPE Auxiliary R2 
GLM “dynamic version” 
Non IV estimation (N=242,049) 
158.278 
(6.83)*** 
96.804 
(6.24)*** 
51.102 
(5.92)*** 173,368 445.59 0.572 
GLM “dynamic version” 
IV estimation (N=242,049) 
206.480 
(16.95)*** 
174.690 
(16.17)*** 
136.022 
(12.19)*** 174,247 461.10 0.571 
Notes: IE stands for incremental effect. Severe obesity: BMI≥35 kg/m2; moderate obesity: 30≤BMI<35 kg/m2; 
overweight: 25≤BMI<30 kg/m2; normal weight (reference category): 18.5≤BMI<25 kg/m2. Auxiliary R2 denotes 
the R-squared from a regression of actual costs on the predicted values; RMSE denotes the root mean squared 
error; MAPE is the mean absolute prediction error. Estimations account for an extensive list of covariates, health 
district dummies and time dummy variables. Regressions contain one-year lagged obesity/overweight rates. IEs 
have been bootstrapped (number of replications set at 200). N sample units refers to the second part. ***p<0.01; 
**p<0.05; *p<0.10 
